Arkadios Wealth Advisors Acquires Shares of 2,485 DexCom, Inc. $DXCM

Arkadios Wealth Advisors bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 2,485 shares of the medical device company’s stock, valued at approximately $217,000.

Several other large investors have also recently modified their holdings of DXCM. Nuveen LLC purchased a new stake in shares of DexCom during the 1st quarter valued at approximately $554,893,000. Jennison Associates LLC raised its holdings in DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after acquiring an additional 2,879,489 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in DexCom by 171.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock valued at $218,175,000 after acquiring an additional 2,015,971 shares during the period. Federated Hermes Inc. lifted its position in shares of DexCom by 2,371.4% during the first quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company’s stock worth $136,220,000 after acquiring an additional 1,914,019 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after acquiring an additional 1,868,241 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on DXCM shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a research note on Wednesday, October 8th. Morgan Stanley lifted their target price on DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. BTIG Research lowered their price target on shares of DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, October 31st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Finally, Oppenheimer cut shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $89.33.

Insider Transactions at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kyle Malady sold 667 shares of the company’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares of the company’s stock, valued at $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 5,383 shares of company stock worth $434,274. Company insiders own 0.32% of the company’s stock.

DexCom Trading Down 2.1%

Shares of DexCom stock opened at $58.02 on Friday. DexCom, Inc. has a 1 year low of $56.44 and a 1 year high of $93.25. The firm has a market cap of $22.63 billion, a PE ratio of 40.29, a PEG ratio of 1.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a 50 day simple moving average of $69.65 and a two-hundred day simple moving average of $77.65.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. Analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.